uniQure (QUREN) AI Stock Analysis

Company Guidance

The company provided clear near-term regulatory and programmatic guidance: uniQure is on track to submit a BLA for AMT‑130 in Q3 2026 (and an MAA to the MHRA in Q3), with the FDA agreeing that the 3‑year Phase I/II data can serve as the primary basis for accelerated approval but asking that the confirmatory randomized, standard‑of‑care‑controlled trial (with total functional capacity at 36 months as the proposed primary endpoint) be aligned and well underway—or potentially fully enrolled—around the time of approval; uniQure intends to initiate that global confirmatory study ASAP. Key data milestones include a June 30, 2026 data cutoff for the planned 4‑year AMT‑130 analysis to be presented in September (analysis to include 12 high‑ and 12 low‑dose patients at 4 years plus 3 additional high‑dose patients with 3‑year follow‑up, cUHDRS/TFC comparisons vs a ~26,000‑participant Enroll‑HD natural history pool, and CSF NfL change). For other programs, AMT‑260 low‑dose cohort data (May 29, 2026 cutoff) showed 3 of 6 patients with 79–100% reductions in disabling seizures in months 4–6 (others −33% to +36%), no related SAEs, and higher‑dose cohort enrollment expected to complete imminently with updates in H1 2027; AMT‑191 (March 15, 2026 cutoff) has 11 dosed patients across 3 dose levels with dose‑dependent alpha‑Gal A increases, stable plasma lyso‑Gb3, all 11 off ERT, but 2 Grade‑3 LFTs in the mid‑dose cohort confirmed as DLTs (resolved with immunosuppression by end‑May 2026) and mid/high dosing paused pending an FDA monitoring/management plan. Financially, Q2 revenue was $5.8M (vs. $5.3M YoY), R&D expense $34.0M (vs. $35.4M), SG&A $17.4M (vs. $13.5M), and cash/investments were $810.3M as of June 30, 2026 (up from $622.5M at 12/31/25), which the company expects to fund operations into 2030; AMT‑130 holds Breakthrough, RMAT and Fast Track designations and priority review will be requested at submission.